25 October 2024
VIVEbiotech publishes new research paper
We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of...
GMP CDMO focused on different stages of the process.
We work exclusively in lentivirus, offering comprehensive services.
Technical adaptation and timely slot availability for each project.
Compliance with EMA and FDA regulatory requirements.
in the US, Europe, Asia and Australia
in reactor since 2020
since 2018
exclusively to lentivirus production
combining young talent and experience
We are a Contract Development and Manufacturing Organization (CDMO) with over 40 biotech companies worldwide that have placed their trust in us.
Read moreVIVEbiotech is one of the only companies in the world specialized exclusively in lentiviral vectors. One of the things that sets us apart is our expertise not only in production but also virology, backed by a team of professionals with more than 30 years of experience.
Read more25 October 2024
We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of...
24 October 2024
The European Society of Gene and Cell Therapy´s annual congress is in full swing.